US FDA Authorizes Lilly’s COVID-19 mAB Combo For Lower Doses Than Tested In Phase III
Executive Summary
The doses of bamlanivimab and etesevimab authorized for use in combination are a fraction of those shown to be effective in the Phase III BLAZE-1 trial; however, Phase II data, PK/PD modeling and in vitro data suggest the lower doses will have the same clinical impact as the higher-dose regimen, the FDA said.
You may also be interested in...
US FDA Lowers Bar for Latest COVID Monoclonal Antibody Authorization
Lilly appeared to benefit from agency’s increased familiarity in treating COVID-19 with these types of biologics. Changing nature of the pandemic and the loss of utility of older antibodies due to the Omicron variant may have also played a role in the data required for latest EUA.
Antibody COVID-19 Therapies Back in China Spotlight Amid Infection Surge
Chinese developers forge ahead with research into antibody therapies for COVID-19 as coronavirus variants gain a toe-hold in the country.
Lilly And GSK/Vir Antibody Combo Reduces COVID-19 Viral Load
Top-line Phase II data show that a combo of bamlanivimab and VIR-7831, neutralizing antibodies to the SARS-CoV-2 spike protein, yielded a relative 70% reduction in viral load.